AI-generated analysis. Always verify with the original filing.
Rocket Pharmaceuticals, Inc. entered into a Sales Agreement on March 10, 2026, and upon entry terminated its prior at-the-market sales agreement with Cowen. The filing includes exhibits consisting of an opinion from K&L Gates LLP and the Sales Agreement, both dated March 10, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On March 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreeme
. Termination of a Material Definitive Agreement. Upon entry into the Sales Agreement, the Company terminated its prior “at-the-market” sales agreement with Cow
. Financial Statements and Exhibits. (d) Exhibits. 5.1 Opinion of K&L Gates LLP, dated March 10, 2026 10.1 Sales Agreement, dated March 10, 2026, by and between
Material Agreement